Nano Holdings, Inc. (4571) Other
Market cap
¥8.2B
P/E ratio
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Return on Assets | - | - | - | - | -7.7 | -6.5 | -7.6 | -4.3 | -10 | -4.6 | -6.3 | -4.8 | -0.8 | -5.3 | -6 |
| Return on equity (%) | - | - | - | ||||||||||||
| Employees | 29 | 36 | 40 | 48 | 55 | 58 | 51 | 42 | 29 | 27 | 24 | 17 | 18 | 20 | 23 |